<DOC>
	<DOCNO>NCT01761786</DOCNO>
	<brief_summary>Rationale : use antiplatelet drug ( i.e . clopidogrel , ticagrelor prasugrel ) crucial treatment patient undergo percutaneous coronary intervention ( PCI ) stent implantation prevent atherothrombotic event . Ticagrelor prasugrel effective prevent atherothrombotic event , high risk bleed complication , compare clopidogrel . Clopidogrel convert active metabolite CYP2C19 . Carriers non functional CYP2C19*2 *3 allele impair CYP2C19 capacity , make clopidogrel less effective . For subject ticagrelor prasugrel alternative . Objective : ass efficacy , safety cost-effectiveness CYP2C19 genotype guide antiplatelet treatment strategy , use clopidogrel non-carriers CYP2C19*2 *3 allele ticagrelor prasugrel carrier CYP2C19*2 *3 allele STEMI patient . Intervention : intervention group genotyped CYP2C19*2 *3 allele variant within 48 hour PCI . Carriers receive either ticagrelor ( 90 mg twice daily ) prasugrel ( 10 mg daily 5 mg daily patient old 75 year body weight &lt; 60 kg ) , accord local standard . Non-carriers treat clopidogrel ( 75 mg daily ) . The control group receive either ticagrelor prasugrel , accord local standard dosage CYP2C19*2 *3 carrier intervention group . The antiplatelet drug continue one year PCI . The follow-up duration one year use follow-up questionnaire .</brief_summary>
	<brief_title>Cost-effectiveness Genotype Guided Treatment With Antiplatelet Drugs STEMI Patients : Optimization Treatment</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
	<criteria>21 year age symptom acute myocardial infarction 30 minute less 12 hour perform primary PCI stenting STEMI unable give inform consent life expectancy le one year active malignancy increase bleeding risk , investigator 's opinion woman know pregnant give birth within past 90 day breastfeed received thrombolytic therapy within previous 24 hour oral anticoagulant previous 7 day severe renal function impairment need dialysis confirm persistent severe hypertension ( Systolic Blood Pressure ( SBP ) &gt; 180 mmHg and/or Diastolic Blood Pressure ( DBP ) &gt; 110 mmHg ) randomization contraindication anticoagulation increase bleeding risk , investigator 's opinion cardiogenic shock ( SBP â‰¤ 80mmHg &gt; 30 min ) need IntraAortic Balloon Pump ( IABP ) history major surgery , severe trauma , fracture organ biopsy within 90 day prior randomisation clinically significant range value platelet count haemoglobin screening , investigator 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Heart Diseases</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Embolism Thrombosis</keyword>
	<keyword>Genetic Testing</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Prasugrel</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Platelet Aggregation Inhibitors</keyword>
	<keyword>Purinergic P2Y Receptor Antagonists</keyword>
</DOC>